There have been also attempts to target components of the ubiquitin-proteasome system in AML: the MDM2 (E3 ligase) antagonist RG7112 exerts antileukemic effects by stabilizing p53 (Roche, phase 1) [18]. Here, TP53 is linked to acute myeloid leukemia.